Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

R C Spiller, D Jenkins, J P Thornley, J M Hebden, T Wright, M Skinner, K R Neal, R C Spiller, D Jenkins, J P Thornley, J M Hebden, T Wright, M Skinner, K R Neal

Abstract

Background and aims: Post-dysenteric irritable bowel syndrome (PD-IBS) develops in up to 25% of patients following Campylobacter enteritis. Our aim was to define the pathological basis of this subgroup of IBS.

Methods: Twenty one patients (group 1) underwent serial rectal biopsy and gut permeability testing following acute Campylobacter enteritis as did 10 PD-IBS patients (group 2) and 12 asymptomatic controls.

Results: In group 1, enteroendocrine cell (EC) numbers were markedly increased initially and at six and 12 weeks (p<0.001) compared with controls. Gut permeability, as assessed by the lactulose/mannitol ratio, was significantly elevated, initially and at 12 weeks (p<0.005). CD3, CD4, and CD8 lymphocyte counts in the lamina propria and intraepithelial lymphocytes (IEL) were significantly increased initially compared with controls. At visit 1, EC numbers were positively correlated with CD3 counts (r=0.6, p=0.01). At one year, seven subjects (five with persistent loose stools) had rectal biopsies which showed significantly elevated EC, CD3, and IEL counts. In group 2, EC and IEL counts were significantly increased compared with controls (p<0.001), as was gut permeability (p<0.01).

Conclusion: Increased EC, T lymphocytes, and gut permeability are acute changes following Campylobacter enteritis which can persist for more than a year and may contribute to PD-IBS.

Figures

Figure 1
Figure 1
(A) Enteroendocrine cell counts per 100 epithelial cells in the patient cohort at visits 1, 2, and 3 compared with controls and post-dysenteric irritable bowel syndrome (PD-IBS) patients. ***Significantly increased compared with controls, p

Figure 1

(A) Enteroendocrine cell counts per…

Figure 1

(A) Enteroendocrine cell counts per 100 epithelial cells in the patient cohort at…

Figure 1
(A) Enteroendocrine cell counts per 100 epithelial cells in the patient cohort at visits 1, 2, and 3 compared with controls and post-dysenteric irritable bowel syndrome (PD-IBS) patients. ***Significantly increased compared with controls, p

Figure 2

CD3 staining lamina propria lymphocytes.…

Figure 2

CD3 staining lamina propria lymphocytes. ***p

Figure 2
CD3 staining lamina propria lymphocytes. ***p

Figure 3

Intraepithelial lymphocytes stained for the…

Figure 3

Intraepithelial lymphocytes stained for the CD8 marker. **Significantly elevated compared with controls. Differences…

Figure 3
Intraepithelial lymphocytes stained for the CD8 marker. **Significantly elevated compared with controls. Differences from control were no longer significant at visits 2 and 3. Post-dysenteric irritable bowel syndrome (PD-IBS) patients also showed significant increases.

Figure 4

Macrophages counts (CD68 positive) showed…

Figure 4

Macrophages counts (CD68 positive) showed a marked decline at visit 1. ***p

Figure 4
Macrophages counts (CD68 positive) showed a marked decline at visit 1. ***p
Similar articles
Cited by
References
    1. Dig Dis Sci. 1989 Aug;34(8):1193-8 - PubMed
    1. Infect Immun. 1997 Apr;65(4):1486-96 - PubMed
    1. Neurogastroenterol Motil. 1996 Dec;8(4):319-31 - PubMed
    1. J Clin Pathol. 1997 Feb;50(2):93-105 - PubMed
    1. Lancet. 1996 Jan 20;347(8995):150-3 - PubMed
Show all 43 references
Publication types
MeSH terms
Related information
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 1
Figure 1
(A) Enteroendocrine cell counts per 100 epithelial cells in the patient cohort at visits 1, 2, and 3 compared with controls and post-dysenteric irritable bowel syndrome (PD-IBS) patients. ***Significantly increased compared with controls, p

Figure 2

CD3 staining lamina propria lymphocytes.…

Figure 2

CD3 staining lamina propria lymphocytes. ***p

Figure 2
CD3 staining lamina propria lymphocytes. ***p

Figure 3

Intraepithelial lymphocytes stained for the…

Figure 3

Intraepithelial lymphocytes stained for the CD8 marker. **Significantly elevated compared with controls. Differences…

Figure 3
Intraepithelial lymphocytes stained for the CD8 marker. **Significantly elevated compared with controls. Differences from control were no longer significant at visits 2 and 3. Post-dysenteric irritable bowel syndrome (PD-IBS) patients also showed significant increases.

Figure 4

Macrophages counts (CD68 positive) showed…

Figure 4

Macrophages counts (CD68 positive) showed a marked decline at visit 1. ***p

Figure 4
Macrophages counts (CD68 positive) showed a marked decline at visit 1. ***p
Similar articles
Cited by
References
    1. Dig Dis Sci. 1989 Aug;34(8):1193-8 - PubMed
    1. Infect Immun. 1997 Apr;65(4):1486-96 - PubMed
    1. Neurogastroenterol Motil. 1996 Dec;8(4):319-31 - PubMed
    1. J Clin Pathol. 1997 Feb;50(2):93-105 - PubMed
    1. Lancet. 1996 Jan 20;347(8995):150-3 - PubMed
Show all 43 references
Publication types
MeSH terms
Related information
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

Follow NCBI
Figure 2
Figure 2
CD3 staining lamina propria lymphocytes. ***p

Figure 3

Intraepithelial lymphocytes stained for the…

Figure 3

Intraepithelial lymphocytes stained for the CD8 marker. **Significantly elevated compared with controls. Differences…

Figure 3
Intraepithelial lymphocytes stained for the CD8 marker. **Significantly elevated compared with controls. Differences from control were no longer significant at visits 2 and 3. Post-dysenteric irritable bowel syndrome (PD-IBS) patients also showed significant increases.

Figure 4

Macrophages counts (CD68 positive) showed…

Figure 4

Macrophages counts (CD68 positive) showed a marked decline at visit 1. ***p

Figure 4
Macrophages counts (CD68 positive) showed a marked decline at visit 1. ***p
Similar articles
Cited by
References
    1. Dig Dis Sci. 1989 Aug;34(8):1193-8 - PubMed
    1. Infect Immun. 1997 Apr;65(4):1486-96 - PubMed
    1. Neurogastroenterol Motil. 1996 Dec;8(4):319-31 - PubMed
    1. J Clin Pathol. 1997 Feb;50(2):93-105 - PubMed
    1. Lancet. 1996 Jan 20;347(8995):150-3 - PubMed
Show all 43 references
Publication types
MeSH terms
Related information
Full text links [x]
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Figure 3
Figure 3
Intraepithelial lymphocytes stained for the CD8 marker. **Significantly elevated compared with controls. Differences from control were no longer significant at visits 2 and 3. Post-dysenteric irritable bowel syndrome (PD-IBS) patients also showed significant increases.
Figure 4
Figure 4
Macrophages counts (CD68 positive) showed a marked decline at visit 1. ***p

References

    1. Dig Dis Sci. 1989 Aug;34(8):1193-8
    1. Infect Immun. 1997 Apr;65(4):1486-96
    1. Neurogastroenterol Motil. 1996 Dec;8(4):319-31
    1. J Clin Pathol. 1997 Feb;50(2):93-105
    1. Lancet. 1996 Jan 20;347(8995):150-3
    1. Am J Surg. 1994 Jun;167(6):570-4
    1. Lancet. 1987 Apr 25;1(8539):963-5
    1. Gut. 1982 Jan;23(1):42-8
    1. Dig Dis Sci. 1993 Sep;38(9):1590-5
    1. Scand J Gastroenterol. 1977;12(3):363-7
    1. J Exp Med. 1998 Mar 16;187(6):855-64
    1. Gastroenterology. 1992 Jun;102(6):1962-7
    1. N Engl J Med. 1993 Oct 7;329(15):1073-8
    1. Trans R Soc Trop Med Hyg. 1994 May-Jun;88(3):269-73
    1. Gastroenterology. 1996 Jan;110(1):147-54
    1. Gut. 1998 Jan;42(1):42-6
    1. Aliment Pharmacol Ther. 1998 Sep;12(9):849-55
    1. J Infect. 1994 Jul;29(1):1-3
    1. Q J Med. 1962 Jul;31:307-22
    1. BMJ. 1999 Feb 27;318(7183):565-6
    1. Hum Pathol. 1989 Jan;20(1):18-28
    1. Gut. 1999 Mar;44(3):400-6
    1. Aliment Pharmacol Ther. 1996 Aug;10(4):595-9
    1. Gut. 1994 May;35(5):669-74
    1. Gastroenterology. 1990 Jul;99(1):83-9
    1. BMJ. 1997 Mar 15;314(7083):779-82
    1. Gastroenterology. 1994 May;106(5):1184-9
    1. Gut. 1996 Oct;39(4):528-31
    1. J Immunol. 1997 Apr 15;158(8):3626-34
    1. J Exp Med. 1995 Oct 1;182(4):1079-88
    1. Gastroenterology. 1998 Jul;115(1):182-205
    1. Gut. 1996 Mar;38(3):337-47
    1. Br Med J (Clin Res Ed). 1982 Jul 3;285(6334):20-1
    1. Gut. 1980 Jun;21(6):512-8
    1. Aliment Pharmacol Ther. 1992 Jun;6(3):273-89
    1. Gut. 1987 Feb;28(2):166-70
    1. Gastroenterology. 1985 Nov;89(5):1070-7
    1. Behav Brain Res. 1996;73(1-2):193-7
    1. Lancet. 1990 Jun 30;335(8705):1555-7
    1. Mayo Clin Proc. 1992 Aug;67(8):732-8
    1. Gastroenterology. 1992 Jun;102(6):1913-9
    1. Gastroenterology. 1991 Jul;101(1):31-8
    1. Nature. 1997 Oct 16;389(6652):737-42

Source: PubMed

Подписаться